** Hong Kong shares of CanSino Biologics Inc 6185.HK climb 2.8% to HK$29, the highest since Jan. 7; on course for third straight session of gains
** Clinical-stage vaccine company estimates its 2024 net loss narrowing to 335-385 mln yuan ($45.80-$52.63 mln) range from 1.48 bln yuan loss in 2023, with revenue amounting to 825-865 mln yuan range, as compared to 2023's 357.1 mln yuan revenue
** "During the reporting period, the group mainly focused on advancing commercialization of the meningococcal conjugate vaccines and the development of non-COVID-19 vaccine candidates" - CanSino
** Shanghai-listed stock 688185.SS rises 2.4% to 58.78 yuan, highest since Jan. 7; set for the second session of rise
** In China, the blue-chip CSI 300 Index .CSI300 gains 0.9% and the Shanghai Composite Index .SSEC adds 0.5%
** In Hong Kong, the healthcare index .HSCIH jumped 2.5% and Hang Seng Index .HSI rises 2.3%
** Last year, CanSino's Hong Kong stock rose 33.8%, while Shanghai shares fell 18.1%
($1 = 7.3148 yuan)
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。